Cargando…

Preclinical and Clinical Investigations of Mood Stabilizers for Huntington's Disease: What Have We Learned?

Huntington's disease (HD) is a lethal, autosomal dominant neurodegenerative disorder caused by CAG repeat expansions at exon 1 of the huntingtin (Htt) gene, which encodes for a mutant huntingtin protein (mHtt). Prominent symptoms of HD include motor dysfunction, characterized by chorea; psychia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheuing, Lisa, Chiu, Chi-Tso, Liao, Hsiao-Mei, Linares, Gabriel R., Chuang, De-Maw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183923/ https://www.ncbi.nlm.nih.gov/pubmed/25285035 http://dx.doi.org/10.7150/ijbs.9898

Ejemplares similares

The Mood Stabilizer Lithium Potentiates the Antidepressant-Like Effects and Ameliorates Oxidative Stress Induced by Acute Ketamine in a Mouse Model of Stress
por: Chiu, Chi-Tso, et al.
Publicado: (2015)

Antidepressant mechanism of ketamine: perspective from preclinical studies
por: Scheuing, Lisa, et al.
Publicado: (2015)

Taming the Huntington’s Disease Proteome: What Have We Learned?
por: Seeley, Connor, et al.
Publicado: (2021)

Large Animal Models of Huntington’s Disease: What We Have Learned and Where We Need to Go Next
por: Howland, David, et al.
Publicado: (2020)

Aura and Stroke: relationship and what we have learnt from preclinical models
por: Yemisci, Muge, et al.
Publicado: (2019)

GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke
por: Chuang, De-Maw, et al.
Publicado: (2011)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
por: Vieira, Jose Gilberto H.
Publicado: (2012)

The diagnosis of premenstrual mood disorders: Do we have it backwards?
por: Phillips, Nancy
Publicado: (2019)

What do we know about Late Onset Huntington’s Disease?
por: Chaganti, Sai S., et al.
Publicado: (2017)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

Lipoabdominoplasty: What We Have Implemented and What We Have Modified over 26 Years
por: Cárdenas-Camarena, Lázaro, et al.
Publicado: (2023)

Population Equation: Balancing What We Need With What We Have
por: Dahl, Richard
Publicado: (2005)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Artificial Intelligence in Urooncology: What We Have and What We Expect
por: Froń, Anita, et al.
Publicado: (2023)

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
por: Molnar, Maria Judit, et al.
Publicado: (2022)

Neutrinos, what we have learned about them and what we have learned using them
por: Steinberger, J
Publicado: (2013)

Dry eye disease revisited: What have we missed?
por: Sun, Chi-Chin
Publicado: (2019)

GOAL: What Have We Learned?
por: Leek, Timothy K Vander
Publicado: (2005)

What have we learned on mesons?
por: Moebes, J P
Publicado: (1972)

What Shall We Have for Breakfast?
Publicado: (1890)

SARS: What have we learned?
Publicado: (2003)

Asthma in the elderly: what we know and what we have yet to know
por: Yáñez, Anahí, et al.
Publicado: (2014)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is dramatically elevated in neurons by mood stabilizers
por: Leng, Yan, et al.
Publicado: (2014)

Phonatory Dysfunction as a Preclinical Symptom of Huntington Disease
por: Rusz, Jan, et al.
Publicado: (2014)

Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms
por: Pla, Patrick, et al.
Publicado: (2014)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

MicroRNAs and cancer: what we know and what we still have to learn
por: Calin, George A
Publicado: (2009)

Erratum: asthma in the elderly: what we know and what we have yet to know
por: Yáñez, Anahí, et al.
Publicado: (2014)

What We Have Learned from Animal Models to Understand the Etiology and Pathology of Endometrioma-Related Infertility
por: Tan, Zhouyurong, et al.
Publicado: (2022)

What have we learned from LEP?
Publicado: (2001)

What have we learned from LEP?
Publicado: (2001)

What have we learned from LEP?
por: Ellis, Jonathan Richard
Publicado: (2001)

Genetics of Obesity: What have we Learned?
por: Choquet, Hélène, et al.
Publicado: (2011)

Higgs sector: What we have learned
por: Fiorini, Luca
Publicado: (2020)

Phage Therapy: What Have We Learned?
por: Górski, Andrzej, et al.
Publicado: (2018)

COVID-19: what have we learned?
por: Ho, Yeh-Li, et al.
Publicado: (2020)

Endometriosis and Reproduction: What We Have Learned
por: Garcia-Fernandez, Jaime, et al.
Publicado: (2020)

Defining transposition: What have we learnt?
por: Roderick, Max E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qfnhjpmmqtddmnskb3aih2qce1